Epidermal Growth Factor (egf) Or Epidermal Growth Factor-like Or Derivative Patents (Class 514/9.6)
-
Patent number: 11058902Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.Type: GrantFiled: February 12, 2018Date of Patent: July 13, 2021Assignees: 9 METERS BIOPHARMA, INC., NORTH CAROLINA STATE UNIVERSITYInventors: Jay P. Madan, Anthony Blikslager, Sandeep Laumas
-
Patent number: 10758560Abstract: Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.Type: GrantFiled: December 8, 2016Date of Patent: September 1, 2020Assignee: Societe des Produits Nestle S.A.Inventors: Alice Pannerec, Jerome Feige
-
Patent number: 10037874Abstract: Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.Type: GrantFiled: November 10, 2015Date of Patent: July 31, 2018Assignees: Biodesix, Inc., The Board of Regents of the University of Texas SystemInventors: Joanna Röder, Carlos Oliveira, Julia Grigorieva, Heinrich Röder, Devalingam Mahalingam
-
Patent number: 9114094Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.Type: GrantFiled: October 28, 2013Date of Patent: August 25, 2015Assignee: TIANJIN SINOBIOTECH LTD.Inventors: Yan Fu, Zailin Yu
-
Publication number: 20150140005Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Inventors: Keith R. Walley, John H. Boyd, James A. Russell
-
Publication number: 20150141332Abstract: Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), and epidermal growth factor (EGF). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid. Methods include diagnosing osteoarthritis, and methods for assessing the severity of osteoarthritis, such as in subject that have been diagnosed with osteoarthritis using radiographic or other methods. Methods may also include comparison of measured cytokine levels to a reference level. Methods of managing the clinical progression of osteoarthritis include initiating a clinical action based on the difference between the measured cytokine level and a reference level.Type: ApplicationFiled: June 4, 2013Publication date: May 21, 2015Applicant: Biomet Biologics, LLCInventor: Krista Toler
-
Publication number: 20150133379Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.Type: ApplicationFiled: April 30, 2014Publication date: May 14, 2015Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
-
Patent number: 9029328Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.Type: GrantFiled: March 24, 2011Date of Patent: May 12, 2015Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of TechnologyInventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
-
Publication number: 20150119326Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.Type: ApplicationFiled: October 24, 2014Publication date: April 30, 2015Inventors: GEORGE P. TUSZYNSKI, JOHN F. WONG, TAFFY WILLIAMS
-
Publication number: 20150094262Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.Type: ApplicationFiled: April 24, 2013Publication date: April 2, 2015Applicants: Hitachi Chemical Company, Ltd., St. Marianna University, School of Medicine, National Institute of Agrobiological SciencesInventors: Kazutoshi Kobayashi, Kunihiro Suto, Naosuke Sumi, Hajime Inoue, Yasushi Tamada
-
Publication number: 20150080301Abstract: Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.Type: ApplicationFiled: November 20, 2014Publication date: March 19, 2015Inventor: Rao S. Bezwada
-
Publication number: 20150080304Abstract: Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8).Type: ApplicationFiled: September 10, 2014Publication date: March 19, 2015Inventor: Ping Wang
-
Publication number: 20150065418Abstract: The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin.Type: ApplicationFiled: May 6, 2014Publication date: March 5, 2015Applicant: Zensun (Shanghai) Science & Technology LimitedInventor: Mingdong ZHOU
-
Patent number: 8968716Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: GrantFiled: September 2, 2010Date of Patent: March 3, 2015Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20150050332Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.Type: ApplicationFiled: November 3, 2014Publication date: February 19, 2015Inventor: Shai Yehoshua Schubert
-
Publication number: 20150051146Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.Type: ApplicationFiled: March 19, 2013Publication date: February 19, 2015Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
-
Publication number: 20150044166Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary stem cell derived factors include, but are not limited to, growth factors, chemokines, and cytokines. The mammal may be a horse, dog, camel, or Homo sapiens.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventor: Michael Riddle, JR.
-
Publication number: 20150031611Abstract: There are provided mutants prepared by changing a DNA base sequence and an amino acid sequence of an epidermal growth factor (EGF), in which a mutant EGF protein has excellent thermal stability and stability even in the state of an aqueous solution, and a gene encoding the protein are provided; a recombinant vector including the gene and a microorganism transformed by the recombinant vector are provided; a method of preparing the mutant EGF protein is provided; a cosmetic composition for accelerating the growth of skin cell and skin regeneration, including the protein, the gene, or the recombinant vector, is provided; and by preparing a product using the EGF mutant according to the present invention, it is possible to produce functional cosmetics, in which the activity thereof is maintained even during a distribution and storage process unlike the conventional wild-type EGF product.Type: ApplicationFiled: February 4, 2014Publication date: January 29, 2015Applicant: PnP Biopharm Co., Ltd.Inventors: Hang-Cheol SHIN, Dong-Hwan KIM, Ha A Rin CHUN, Seung-Taek SUN
-
Publication number: 20150031610Abstract: Described herein are compositions comprising a derivatized polyglucosamine and a small molecule, peptide, or protein and related methods of use, e.g., to deliver a small molecule, peptide, or protein to cells (e.g., cancer cells) or tissues (e.g., mucosal membrane and epithelial membrane), e.g., to treat a disease or condition in a subject.Type: ApplicationFiled: March 4, 2013Publication date: January 29, 2015Inventors: Shenda M. Baker, William P. Wiesmann, Ruth Baxter
-
Publication number: 20150031612Abstract: The present invention includes a novel class of allosteric modulators that target a protein having a juxtamembrane segment. In another embodiment, the allosteric modulator is a peptide mimetic that is capable of interacting with an ?-helix or a coiled coil domain of a protein. In one embodiment, the peptide mimetic binds to at least an ?-helix or a coiled coil domain of EGFR and modulates its activity.Type: ApplicationFiled: July 25, 2014Publication date: January 29, 2015Inventor: Alanna Schepartz
-
Publication number: 20140379094Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.Type: ApplicationFiled: May 16, 2014Publication date: December 25, 2014Applicants: TRUSTEES OF TUFTS COLLEGE, UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE AFM, UNIVERSITY OF ILLINOIS AT CHICAGOInventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
-
Publication number: 20140364366Abstract: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.Type: ApplicationFiled: October 8, 2012Publication date: December 11, 2014Inventor: Mingdong Zhou
-
Publication number: 20140364365Abstract: A mask for skin care includes a fiber substrate, wherein the fiber substrate is woven or nonwoven, and includes modified fibers, and the modified fibers are cellulose fibers with at least one hydrophilic functional group grafted on. The grafted ratio of the modified fibers is in the range from 5% to 30%, and the modified fibers can effectively improve the moisture absorption and the moisture-retaining capacity of the mask for skin care.Type: ApplicationFiled: March 17, 2014Publication date: December 11, 2014Applicant: Far Eastern New Century CorporationInventors: Yong-Yi Wu, Mei-Ting Fan Chiang, Zij-Jyun Fang
-
Publication number: 20140357559Abstract: A strain-hardened interpenetrating polymer network (IPN) hydrogel is provided. The interpenetrating polymer network hydrogel is based on two different networks. The first network is a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups. The second network is a non-silicone network of ionizable monomers. The second network has been polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. An aqueous salt solution having a neutral pH is used to ionize and swell the second network in the interpenetrating polymer network. The swelling of the second network is constrained by the first network, and this constraining effect results in an increase in effective physical cross-links within the interpenetrating polymer network, and, in turn, an increase its elastic modulus.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventors: David Myung, Laura Hartmann, Jaan Noolandi, Christopher N. Ta, Curtis W. Frank
-
Publication number: 20140356323Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Laura E. Niklason, Yuling Li, Juliana Blum, Shannon L.M. Dahl, Geoffrey Erickson, Frank Zeigler
-
Publication number: 20140348899Abstract: A medicament for treating cystitis and a method of treatment are provided. The medicament comprises a stromal vascular fraction provided in a liposomal carrier. Optionally, the medicament also controls one or more additional agents, such as a growth factor, glycosaminoglycan, DMSO, and/or another small molecule used to treat cystitis or having an effect on human stem cells. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament. The SVF can be derived from a patient's own adipose cells via liposuction.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: Nanologix Research, LLCInventors: Elliot B. Lander, Jackie R. See
-
Publication number: 20140348936Abstract: Gastroretentive controlled release vehicles may, in some embodiments, (1) comprise a polymeric matrix and agents for the treatment, prevention, and/or mitigation of a disease and/or side effect thereof and (2) have both gastroretentive properties and controlled release properties. Preferrably, the polymeric matrix may comprise ethylene copolymers, ethyl celluloses, and/or thermoplastic polyurethanes that may optionally be partially crosslinked.Type: ApplicationFiled: December 17, 2012Publication date: November 27, 2014Inventors: Jose Reyes, Kenneth Anderson, Dale Zevotek, Nathan Reuter, J. Gregory Little, Jeffrey Haley, Vassilios Galiatsatos
-
Publication number: 20140335145Abstract: The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.Type: ApplicationFiled: July 27, 2014Publication date: November 13, 2014Inventors: Sungho JIN, Seunghan OH, Karla BRAMMER
-
Patent number: 8883728Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.Type: GrantFiled: November 24, 2010Date of Patent: November 11, 2014Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Patent number: 8883184Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.Type: GrantFiled: January 20, 2009Date of Patent: November 11, 2014Assignee: Pioneer Surgical Technology, Inc.Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
-
Publication number: 20140322292Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.Type: ApplicationFiled: November 29, 2012Publication date: October 30, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John D. Koerner
-
Patent number: 8871709Abstract: Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required.Type: GrantFiled: June 3, 2010Date of Patent: October 28, 2014Assignee: Queensland University of TechnolgyInventors: Zee Upton, Christopher Luke Towne
-
Publication number: 20140315806Abstract: The present invention relates to veterinary decorin compositions and methods of their production.Type: ApplicationFiled: April 22, 2014Publication date: October 23, 2014Applicant: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck
-
Patent number: 8858939Abstract: The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.Type: GrantFiled: October 1, 2010Date of Patent: October 14, 2014Assignee: Monash UniversityInventors: Stephen Tong, Ulrika W. Nilsson, Terence Grant Johns
-
Patent number: 8841251Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.Type: GrantFiled: January 10, 2012Date of Patent: September 23, 2014Assignee: Centro de Immunologia Molecular (CIM)Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
-
Publication number: 20140271589Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: BIOMET BIOLOGICS, LLCInventors: Andrea MATUSKA, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY
-
Patent number: 8822415Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: July 19, 2013Date of Patent: September 2, 2014Assignee: Stemnion, Inc.Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20140243269Abstract: Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication for effecting neuroprotection in a subject suffering from schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and/or spinal cord injury.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: PROTEOSYS AGInventor: André SCHRATTENHOLZ
-
Publication number: 20140243268Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.Type: ApplicationFiled: February 24, 2014Publication date: August 28, 2014Applicant: Georgia Regents Research Institute, Inc.Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
-
Publication number: 20140243270Abstract: A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: PROTEOSYS AGInventor: André SCHRATTENHOLZ
-
Patent number: 8815277Abstract: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or aniline moiety using a linker. In contrast to conventional hydrogel, the in situ-forming injectable hydrogel is superior in terms of in vivo stability and mechanical strength thanks to the introduction of a water-soluble polymer as a linker which leads to an improvement in the reactivity of phenol or aniline moieties. Having the advantage of superior bio stability and mechanical strength, the hydrogel finds a variety of applications in the biomedical field.Type: GrantFiled: July 1, 2010Date of Patent: August 26, 2014Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park
-
Publication number: 20140228291Abstract: Compositions and methods are provided for a post-procedure care following the treatment of skin with cosmetic skin resurfacing treatments, which include without limitation a variety of laser treatments, chemical peeling and dermabrasion, by applying a silicone-based gel formulation in combination with therapeutic peptides. Peptides of interest include one or more of transforming growth factor, epidermal growth factor, and basic fibroblast growth factor. The formulation may further comprise an effective dose of one or more acylated peptides, which peptides are active in remodeling of the skin.Type: ApplicationFiled: February 11, 2013Publication date: August 14, 2014Applicant: JAN MARINI SKIN RESEARCHInventor: JAN MARINI SKIN RESEARCH
-
Publication number: 20140228290Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.Type: ApplicationFiled: August 2, 2012Publication date: August 14, 2014Applicants: REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
-
Publication number: 20140227337Abstract: The present invention relates to devices and related methods for treating fistulas such as anal or recto-vaginal fistulas, in particular by the use of a seton to secure a tissue growth promoter such as a growth factor and/or fibrin. The various devices are particularly suitable for positioning tissue growth promoters securely within a fistula. Thus, one device comprises a seton and a tissue growth promoter. Further related aspects of the invention included devices comprising an enclosure provided in between portions of a seton, devices comprising a seton and a plurality of holes for enabling the device to be sutured to tissue, devices comprising a probe and a seton that are releasably connectable end-to-end, devices comprising an attachment device to secure the ends of a seton, and devices comprising a fistula plug adapted to be secured to a section.Type: ApplicationFiled: September 26, 2011Publication date: August 14, 2014Applicant: KEIGHLEYCOLO LTDInventor: Michael Robert Burch Keighley
-
Publication number: 20140219953Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: January 2, 2014Publication date: August 7, 2014Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Publication number: 20140221289Abstract: The present invention relates to shear-thinning ?-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.Type: ApplicationFiled: April 10, 2012Publication date: August 7, 2014Applicants: Commissariat a L'energie Atomique et Aux Energies Alternatives, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Vincent Forge, Carole Mathevon, Frédéric Pignon
-
Patent number: 8778879Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.Type: GrantFiled: June 26, 2008Date of Patent: July 15, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Gryssell María Rodríguez Martínez, Lisel Viña Rodríguez, Loany Calvo González, Ariadna Cuevas Fiallo, Ernesto Chico Véliz, Agustín Bienvenido Lage Dávila, Tania Crombet Ramos, Airama Albisa Novo, Gisela Maria González Marinello
-
Publication number: 20140178404Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.Type: ApplicationFiled: August 15, 2012Publication date: June 26, 2014Applicant: CHILDREN'S HOSPITAL LOS ANGELESInventor: Mark R. Frey
-
Patent number: 8754043Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.Type: GrantFiled: June 6, 2013Date of Patent: June 17, 2014Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Publication number: 20140155325Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 20, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha